Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stada Recruits Ex-Sandoz Exec To Help Steer Biosimilars

Christine Berndt Previously Headed Biosimilar Development Programs At Sandoz

Executive Summary

Stada has announced the appointment of former Sandoz executive Christine Berndt as head of global development for specialty and biosimilar products, replacing Michael Mack.

You may also be interested in...



Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo

The Swedish biotech’s patience paid off as it received a positive EU CHMP opinion on its rare nephrology drug Kinpeygo, known elsewhere as Tarpeyo, following delays related to manufacturing questions.

Who’s Hired? Formycon Is Latest To Swap CEO

Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.

Stada Gears Up For Higher-Strength Adalimumab As Alvotech Clears Up Legal Overhang

Alvotech and its strategic partner Stada are preparing to launch their higher-strength adalimumab candidate AVT02 in Europe after settling intellectual property disputes with originator AbbVie.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel